{"transactions":[{"id":4613217,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-09-09T18:37:16.000Z","date":"2026-09-07","kind":"exercise","planned":false,"acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0001437749-26-029965","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926029965/rdgdoc.xml","form_type":"4"}},{"id":4613216,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-09T18:37:16.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":871,"price":42.92,"value":37383.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":59882,"source":{"system":"sec-edgar","filing":"0001437749-26-029965","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926029965/rdgdoc.xml","form_type":"4"}},{"id":4613215,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-09T18:37:16.000Z","date":"2026-09-07","kind":"exercise","planned":false,"acquired":true,"shares":1667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":60753,"source":{"system":"sec-edgar","filing":"0001437749-26-029965","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926029965/rdgdoc.xml","form_type":"4"}},{"id":677450,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"ordinary shares","published_at":"2026-08-24T21:03:17.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":60677,"price":47.05,"value":2854852.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $49.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":59086,"source":{"system":"sec-edgar","filing":"0001437749-26-028840","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926028840/rdgdoc.xml","form_type":"4"}},{"id":711210,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-10T18:17:40.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":40,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":119763,"source":{"system":"sec-edgar","filing":"0001437749-26-023290","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926023290/rdgdoc.xml","form_type":"4"}},{"id":727737,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-24T14:22:49.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":35.01,"value":350100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 and $35.08. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":129763,"source":{"system":"sec-edgar","filing":"0001437749-26-021523","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926021523/rdgdoc.xml","form_type":"4"}},{"id":744711,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-09T17:59:59.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-26-019964","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926019964/rdgdoc.xml","form_type":"4"}},{"id":744710,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-09T17:59:59.000Z","date":"2026-06-08","kind":"sale","planned":false,"acquired":false,"shares":5222,"price":27.3,"value":142560.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":139763,"source":{"system":"sec-edgar","filing":"0001437749-26-019964","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926019964/rdgdoc.xml","form_type":"4"}},{"id":744709,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-09T17:59:59.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":144985,"source":{"system":"sec-edgar","filing":"0001437749-26-019964","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926019964/rdgdoc.xml","form_type":"4"}},{"id":784816,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-05-11T19:54:04.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":30,"value":300000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 and $30.05. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":134985,"source":{"system":"sec-edgar","filing":"0001437749-26-016104","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926016104/rdgdoc.xml","form_type":"4"}},{"id":919480,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-05T00:37:34.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":3686,"price":19.69,"value":72577.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":144985,"source":{"system":"sec-edgar","filing":"0001437749-26-003040","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926003040/rdgdoc.xml","form_type":"4"}},{"id":919479,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-05T00:37:34.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":1843,"price":19.69,"value":36288.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":148671,"source":{"system":"sec-edgar","filing":"0001437749-26-003040","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926003040/rdgdoc.xml","form_type":"4"}},{"id":919478,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-05T00:37:34.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":1844,"price":19.69,"value":36308.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":150514,"source":{"system":"sec-edgar","filing":"0001437749-26-003040","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926003040/rdgdoc.xml","form_type":"4"}},{"id":922005,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029."}],"balance_after":20000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":922004,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":922003,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted RSUs on January 31, 2025 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The reporting person was granted RSUs on January 31, 2025 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026."}],"balance_after":13334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":922002,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025."}],"balance_after":3334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":922001,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":3334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":142359,"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":922000,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":6666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":152358,"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":921999,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-03T22:18:26.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":145692,"source":{"system":"sec-edgar","filing":"0001437749-26-002843","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774926002843/rdgdoc.xml","form_type":"4"}},{"id":992566,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-20T18:42:12.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":25,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":139025,"source":{"system":"sec-edgar","filing":"0001437749-25-035821","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925035821/rdgdoc.xml","form_type":"4"}},{"id":1044861,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-09T22:37:09.000Z","date":"2025-09-07","kind":"exercise","planned":false,"acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024."}],"balance_after":1667,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0001437749-25-028707","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925028707/rdgdoc.xml","form_type":"4"}},{"id":1044860,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-09-09T22:37:09.000Z","date":"2025-09-08","kind":"sale","planned":false,"acquired":false,"shares":871,"price":19.11,"value":16644.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":149025,"source":{"system":"sec-edgar","filing":"0001437749-25-028707","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925028707/rdgdoc.xml","form_type":"4"}},{"id":1044859,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-09-09T22:37:09.000Z","date":"2025-09-07","kind":"exercise","planned":false,"acquired":true,"shares":1667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":149896,"source":{"system":"sec-edgar","filing":"0001437749-25-028707","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925028707/rdgdoc.xml","form_type":"4"}},{"id":1067837,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-08-13T13:58:14.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":17.69,"value":176900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.63 and $17.76. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":148229,"source":{"system":"sec-edgar","filing":"0001437749-25-026377","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925026377/rdgdoc.xml","form_type":"4"}},{"id":1079167,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-30T20:02:05.000Z","date":"2025-07-28","kind":"sale","planned":false,"acquired":false,"shares":5149,"price":19.14,"value":98551.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units."}],"balance_after":158229,"source":{"system":"sec-edgar","filing":"0001437749-25-023961","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925023961/rdgdoc.xml","form_type":"4"}},{"id":1079166,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-30T20:02:05.000Z","date":"2025-07-28","kind":"exercise","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":163378,"source":{"system":"sec-edgar","filing":"0001437749-25-023961","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925023961/rdgdoc.xml","form_type":"4"}},{"id":1115059,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-06-11T13:14:14.000Z","date":"2025-06-08","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024."}],"balance_after":10000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-25-020045","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925020045/rdgdoc.xml","form_type":"4"}},{"id":1115058,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-11T13:14:14.000Z","date":"2025-06-09","kind":"sale","planned":false,"acquired":false,"shares":5162,"price":7.37,"value":38043.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":153378,"source":{"system":"sec-edgar","filing":"0001437749-25-020045","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925020045/rdgdoc.xml","form_type":"4"}},{"id":1115057,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-11T13:14:14.000Z","date":"2025-06-08","kind":"exercise","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":158540,"source":{"system":"sec-edgar","filing":"0001437749-25-020045","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925020045/rdgdoc.xml","form_type":"4"}},{"id":1284980,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028."}],"balance_after":20000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284979,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025."}],"balance_after":6667,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284978,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024."}],"balance_after":3334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284977,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":1334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1334},"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284976,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"sale","planned":false,"acquired":false,"shares":1896,"price":11.14,"value":21121.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":148540,"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284975,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":150436,"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284974,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"sale","planned":false,"acquired":false,"shares":1896,"price":11.14,"value":21121.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":147103,"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284973,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":148999,"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284972,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"sale","planned":false,"acquired":false,"shares":759,"price":11.14,"value":8455.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":145666,"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1284971,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-04T16:53:22.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":1334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":146425,"source":{"system":"sec-edgar","filing":"0001437749-25-002688","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774925002688/rdgdoc.xml","form_type":"4"}},{"id":1408701,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-12T17:54:09.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024."}],"balance_after":3334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001437749-24-029040","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924029040/rdgdoc.xml","form_type":"4"}},{"id":1408700,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-09-12T17:54:09.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":859,"price":13.08,"value":11235.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":145091,"source":{"system":"sec-edgar","filing":"0001437749-24-029040","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924029040/rdgdoc.xml","form_type":"4"}},{"id":1408699,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-09-12T17:54:09.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":145950,"source":{"system":"sec-edgar","filing":"0001437749-24-029040","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924029040/rdgdoc.xml","form_type":"4"}},{"id":1483583,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-11T17:15:23.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024."}],"balance_after":20000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-24-019900","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924019900/rdgdoc.xml","form_type":"4"}},{"id":1483582,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-06-11T17:15:23.000Z","date":"2024-06-10","kind":"sale","planned":false,"acquired":false,"shares":5153,"price":13.08,"value":67401.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":144284,"source":{"system":"sec-edgar","filing":"0001437749-24-019900","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924019900/rdgdoc.xml","form_type":"4"}},{"id":1483581,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-06-11T17:15:23.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":149437,"source":{"system":"sec-edgar","filing":"0001437749-24-019900","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924019900/rdgdoc.xml","form_type":"4"}},{"id":1566029,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-20T20:38:32.000Z","date":"2024-03-18","kind":"sale","planned":false,"acquired":false,"shares":12000,"price":14.05,"value":168600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"A portion of the cash receipts will be used for federal income tax purposes"}],"balance_after":139437,"source":{"system":"sec-edgar","filing":"0001437749-24-008707","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924008707/rdgdoc.xml","form_type":"4"}},{"id":1659015,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-06T02:15:14.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":1894,"price":15.78,"value":29887.32,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024."}],"balance_after":151437,"source":{"system":"sec-edgar","filing":"0001437749-24-003153","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003153/rdgdoc.xml","form_type":"4/A","original_submission_date":"2024-02-02"}},{"id":1659014,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-06T02:15:14.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":758,"price":15.78,"value":11961.24,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024."}],"balance_after":149998,"source":{"system":"sec-edgar","filing":"0001437749-24-003153","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003153/rdgdoc.xml","form_type":"4/A","original_submission_date":"2024-02-02"}},{"id":1659013,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-06T02:15:14.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":1137,"price":15.78,"value":17941.86,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024."}],"balance_after":149423,"source":{"system":"sec-edgar","filing":"0001437749-24-003153","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003153/rdgdoc.xml","form_type":"4/A","original_submission_date":"2024-02-02"}},{"id":1661904,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027."}],"balance_after":10000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661903,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024."}],"balance_after":6667,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661902,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":false,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023."}],"balance_after":1334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661901,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661900,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":1894,"price":15.74,"value":29811.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":151437,"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661899,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":153331,"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661898,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":758,"price":15.74,"value":11930.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":149998,"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661897,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":true,"shares":1333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":150756,"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661896,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":1137,"price":15.74,"value":17896.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":149423,"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1661895,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-03T00:07:36.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":150560,"source":{"system":"sec-edgar","filing":"0001437749-24-003016","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774924003016/rdgdoc.xml","form_type":"4"}},{"id":1784728,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-08T19:40:34.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026"}],"balance_after":5000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001437749-23-025476","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923025476/rdgdoc.xml","form_type":"4"}},{"id":1860705,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-09T19:26:13.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2023."}],"balance_after":30000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-23-017046","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923017046/rdgdoc.xml","form_type":"4"}},{"id":2036342,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026."}],"balance_after":30000,"derivative":{"exercise_price":10.39,"expiration_date":"2033-01-31","underlying":"Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036341,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026."}],"balance_after":10000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036340,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023."}],"balance_after":2667,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036339,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."}],"balance_after":2000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036338,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036337,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":661,"price":10.12,"value":6689.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":148560,"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036336,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":1333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":149221,"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036335,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":991,"price":10.12,"value":10028.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":147888,"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036334,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":148879,"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036333,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":248,"price":10.12,"value":2509.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":146879,"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2036332,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-02T18:02:20.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":147127,"source":{"system":"sec-edgar","filing":"0001437749-23-002336","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923002336/rdgdoc.xml","form_type":"4"}},{"id":2048748,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-24T00:10:39.000Z","date":"2023-01-20","kind":"exercise","acquired":false,"shares":122677,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2019-01-20","expiration_date":"2023-01-20","underlying":"Ordinary Shares","underlying_shares":122677},"source":{"system":"sec-edgar","filing":"0001437749-23-001625","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923001625/rdgdoc.xml","form_type":"4"}},{"id":2048747,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-24T00:10:39.000Z","date":"2023-01-20","kind":"exercise","acquired":true,"shares":122677,"price":5,"value":613385.0,"ownership":{"direct":true},"balance_after":146627,"source":{"system":"sec-edgar","filing":"0001437749-23-001625","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774923001625/rdgdoc.xml","form_type":"4"}},{"id":2127226,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-11-02T20:31:11.000Z","date":"2022-10-31","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":500,"derivative":{"underlying":"Ordinary Shares","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001437749-22-025549","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922025549/rdgdoc.xml","form_type":"4"}},{"id":2127225,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-11-02T20:31:11.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":258,"price":11.85,"value":3057.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":23950,"source":{"system":"sec-edgar","filing":"0001437749-22-025549","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922025549/rdgdoc.xml","form_type":"4"}},{"id":2127224,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-11-02T20:31:11.000Z","date":"2022-10-31","kind":"exercise","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":24208,"source":{"system":"sec-edgar","filing":"0001437749-22-025549","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922025549/rdgdoc.xml","form_type":"4"}},{"id":2173981,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-25T19:25:01.000Z","date":"2022-07-31","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":1000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001437749-22-021337","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922021337/rdgdoc.xml","form_type":"4"}},{"id":2173980,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-25T19:25:01.000Z","date":"2022-08-01","kind":"sale","acquired":false,"shares":259,"price":7.81,"value":2022.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":23708,"source":{"system":"sec-edgar","filing":"0001437749-22-021337","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922021337/rdgdoc.xml","form_type":"4"}},{"id":2173979,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-25T19:25:01.000Z","date":"2022-07-31","kind":"exercise","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":23967,"source":{"system":"sec-edgar","filing":"0001437749-22-021337","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922021337/rdgdoc.xml","form_type":"4"}},{"id":2284436,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-05-03T21:19:03.000Z","date":"2022-04-30","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":1500,"derivative":{"underlying":"Ordinary Shares","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001437749-22-010701","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922010701/rdgdoc.xml","form_type":"4"}},{"id":2284435,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-05-03T21:19:03.000Z","date":"2022-04-30","kind":"sale","acquired":false,"shares":254,"price":6.62,"value":1681.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":23467,"source":{"system":"sec-edgar","filing":"0001437749-22-010701","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922010701/rdgdoc.xml","form_type":"4"}},{"id":2284434,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-05-03T21:19:03.000Z","date":"2022-04-30","kind":"exercise","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":23721,"source":{"system":"sec-edgar","filing":"0001437749-22-010701","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000143774922010701/rdgdoc.xml","form_type":"4"}},{"id":2416884,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."}],"balance_after":4000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416883,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025"}],"balance_after":4000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416882,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":12064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025"}],"balance_after":12064,"derivative":{"exercise_price":7.72,"expiration_date":"2032-01-31","underlying":"Ordinary Shares","underlying_shares":12064},"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416881,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":2000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416880,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":1099,"price":7.58,"value":8330.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":23221,"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416879,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"exercise","acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":24320,"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416878,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":275,"price":7.58,"value":2084.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":22320,"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2416877,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T21:33:42.000Z","date":"2022-01-31","kind":"exercise","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":22595,"source":{"system":"sec-edgar","filing":"0001209191-22-006384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122006384/doc4.xml","form_type":"4"}},{"id":2422613,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-28T21:29:36.000Z","date":"2022-01-26","kind":"exercise","acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0001209191-22-005416","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122005416/doc4.xml","form_type":"4"}},{"id":2422612,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-28T21:29:36.000Z","date":"2022-01-26","kind":"sale","acquired":false,"shares":111,"price":8.09,"value":897.99,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units"}],"balance_after":22095,"source":{"system":"sec-edgar","filing":"0001209191-22-005416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122005416/doc4.xml","form_type":"4"}},{"id":2422611,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-28T21:29:36.000Z","date":"2022-01-26","kind":"exercise","acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":22206,"source":{"system":"sec-edgar","filing":"0001209191-22-005416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919122005416/doc4.xml","form_type":"4"}},{"id":2503032,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-19T20:05:02.000Z","date":"2021-11-18","kind":"purchase","acquired":true,"shares":160,"price":13.1,"value":2096.0,"ownership":{"direct":true},"balance_after":21997,"source":{"system":"sec-edgar","filing":"0001209191-21-065756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919121065756/doc4.xml","form_type":"4"}},{"id":2529055,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T19:45:03.000Z","date":"2021-10-31","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":2500,"derivative":{"underlying":"Ordinary Shares","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-21-062360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919121062360/doc4.xml","form_type":"4"}},{"id":2529054,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-02T19:45:03.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":258,"price":17.16,"value":4427.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units"}],"balance_after":21837,"source":{"system":"sec-edgar","filing":"0001209191-21-062360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919121062360/doc4.xml","form_type":"4"}},{"id":2529053,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-02T19:45:03.000Z","date":"2021-10-31","kind":"exercise","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":22095,"source":{"system":"sec-edgar","filing":"0001209191-21-062360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919121062360/doc4.xml","form_type":"4"}},{"id":2532841,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":20367,"kind":"person","name":"Schoenberg Mark","position":1,"cik":"0001763581","reported_name":"Schoenberg Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-28T18:04:23.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":209,"derivative":{"underlying":"Ordinary Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0001209191-21-061868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763581/000120919121061868/doc4.xml","form_type":"4"}}],"next_cursor":"2021-10-28T18:04:23.000000Z,2532841"}